<DOC>
	<DOCNO>NCT01778634</DOCNO>
	<brief_summary>The purpose study determine whether intravenous azithromycin effective eradicate Ureaplasma respiratory tract infection preterm infant bear 24 28 week gestation .</brief_summary>
	<brief_title>Trial Intravenous Azithromycin Eradicate Ureaplasma Respiratory Tract Infection Preterm Infants</brief_title>
	<detailed_description>The study design double-blind , placebo-controlled clinical trial test efficacy safety azithromycin 20 mg/kg x 3 day eradicate Ureaplasma spp respiratory tract preterm infant 24 week 0 day 28 week 6 day gestation expose positive pressure ventilation . The primary outcome survival microbiological eradication Ureaplasma define survival discharge transfer 3 negative culture obtain post-therapy . Secondary outcome include physiologic BPD 36 week post-menstrual age ( PMA ) , overall mortality , incidence co-morbidities prematurity intraventricular hemorrhage , periventricular leukomalacia , necrotizing enterocolitis , bacterial fungal nosocomial infection , pulmonary air leak , patent ductus arteriosus , retinopathy prematurity , number day positive pressure ventilation , number day oxygen supplementation , use postnatal steroid , use non-study antibiotic . At 6 18 month adjust age , pulmonary outcome questionnaire administer phone person interview . At 18-22 month adjust age , neurodevelopmental outcome assess 1 ) Bayley Scale Infant Toddler Development , 3rd edition ( BSID-III ) ; 2 ) Amiel-Tison neurologic examination ; 3 ) Gross Motor Function Classification System ; 4 ) medical record review hear impairment without amplification vision impairment ( vision &lt; 20/200 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Ureaplasma Infections</mesh_term>
	<criteria>Appropriate size gestational age ( AGA ) Gestational age 24 week 0 days28weeks 6 day best obstetrical estimate &lt; 72 h age Positive pressure ventilation least 1 hour duration first 72 hour life Presence indwell intravenous line drug administration Any patient judge nonviable withdrawal life support plan Patients major lethal congenital anomaly Triplets high order multiple Patients deliver maternal indication ( low risk Ureaplasma colonization ) Patients EKG QT interval correct heart rate ( Qtc ) â‰¥ 450 m Patients significant hepatic impairment ( direct bilirubin &gt; 1.5 mg/dL ) Patients expose systemic macrolide Patients clinically suspect Ureaplasma central nervous system ( CNS ) infection confirm bacterial/viral infection Patients participate clinical trial involve investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>72 Hours</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Ureaplasma parvum</keyword>
	<keyword>Ureaplasma urealyticum</keyword>
	<keyword>prematurity</keyword>
	<keyword>bronchopulmonary dysplasia</keyword>
	<keyword>azithromycin</keyword>
</DOC>